Deeper understanding of DNA repair
mechanisms and their potential value as therapeutic targets in oncology
heralded the clinical development of poly(ADP-ribose) polymerase (PARP)
inhibitors. Although initially developed to exploit synthetic lethality in
models of cancer associated with defective DNA repair, our burgeoning knowledge
of PARP biology has resulted in these agents being exploited both in cancer
with select chemotherapeutic agents and in non-malignant diseases. In this
review article, we briefly review the mechanisms of DNA repair and pre-clinical
development of PARP inhibitors before discussing the clinical development of
the various PARP inhibitors in depth.
Source: Role of PARP inhibitors in
cancer biology and therapy. Davar D, Beumer JH, Hamieh L, Tawbi H. Curr Med
Chem. 2012;19(23):3907-21.
Free paper available at:
Aucun commentaire:
Enregistrer un commentaire